Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Retatrutide's Phase 2, published in the New England Journal of Medicine in 2023, reported approximately 24.2% at 48 weeks (12 mg), and the Phase 3 TRIUMPH-1 readout in 2026 reported near 28% at 80 weeks
Fatigue that worsens after meals or is accompanied by abdominal discomfort may primarily reflect gastrointestinal side effects rather than a distinct energy problem
Lilly has guided to a Q2-Q3 2026 readout for TRIUMPH-1, the pivotal 80-week general-obesity trial
Northwest Face & Body is a premier plastic surgery practice and medical spa located on the shores of Lake Washington
Cautions for the wider drug class Class-level Approved GLP-1 medicines carry label warnings about pancreas inflammation, gallbladder problems, thyroid tumours seen in rodent studies, and low blood sugar when combined with insulin or sulfonylureas (a diabetes drug group)
US$ 21.25
US$ 25.15
US$ 26.49
US$ 25.58
US$ 26.19
